CJC-1295 + GHRP-6 Stack vs Tesamorelin
A neutral, side-by-side comparison of two performance & growth hormone peptides — their mechanisms, dosing ranges, administration routes, side effects, and research evidence. For research and educational purposes only.
CJC-1295 + GHRP-6 Stack
CJC-1295 (GHRH analog) combined with GHRP-6 (potent ghrelin receptor agonist) to produce synergistic GH release via complementary mechanisms. GHRP-6's strong appetite stimulation distinguishes this from the CJC-1295 + Ipamorelin stack, making it preferred for bulking and mass-gaining protocols where caloric surplus is the goal. Produces larger GH pulses than CJC + Ipamorelin but with more pronounced appetite effects.
Full profileTesamorelin
Tesamorelin is an FDA-approved synthetic analog of growth hormone-releasing hormone (GHRH). Approved in 2010 as Egrifta, it is the only GHRH peptide with an approved clinical indication — reduction of excess visceral abdominal fat in people with HIV-associated lipodystrophy. It has the most robust human trial evidence of any growth hormone secretagogue, including dedicated studies on visceral fat and liver fat.
Full profile| CJC-1295 + GHRP-6 Stack | Tesamorelin | |
|---|---|---|
| Category | Performance & Growth Hormone | Performance & Growth Hormone |
| Also known as | CJC GHRP-6 combination, GH releasing stack, GHRH GHRP combination, CJC-1295 GHRP-6 | Egrifta, Egrifta SV, TH9507, GHRH analog |
| Evidence | Research-stage | FDA-approved |
| Dosing range | CJC-1295 100mcg + GHRP-6 100mcg–CJC-1295 200mcg + GHRP-6 300mcg mcg, 1–3x daily (pre-sleep, pre-workout, morning) | 1.28mg–2mg mg, once daily (subcutaneous) |
| Administration | Subcutaneous injection | Subcutaneous injection (abdomen, with site rotation) |
| Key side effects | Strong appetite stimulation (GHRP-6 dominant effect), Water retention, Tingling / numbness in extremities, Mild cortisol elevation (GHRP-6 is less selective than ipamorelin) | Injection site reactions (erythema, pruritus), Peripheral edema, Arthralgia (joint pain), Myalgia |
| Cited sources | 2 references | 5 references |
Key differences
- Evidence level differs: CJC-1295 + GHRP-6 Stack is research-stage, while Tesamorelin is fda-approved.
- Administration: CJC-1295 + GHRP-6 Stack — Subcutaneous injection; Tesamorelin — Subcutaneous injection (abdomen, with site rotation).
- Dosing units differ: CJC-1295 + GHRP-6 Stack is dosed in mcg, Tesamorelin in mg — they operate at different scales.
- Frequency: CJC-1295 + GHRP-6 Stack is typically 1–3x daily (pre-sleep, pre-workout, morning); Tesamorelin is once daily (subcutaneous).
- Research depth: this profile cites 2 sources for CJC-1295 + GHRP-6 Stack vs 5 for Tesamorelin.
How each works
CJC-1295 + GHRP-6 Stack
The GHRH + GHRP combination synergistically amplifies GH pulse amplitude compared to either agent alone. CJC-1295 elevates baseline GH via GHRH receptor signaling at the pituitary; GHRP-6 triggers pulse timing via GHS-R1a. GHRP-6's potent appetite stimulation (significantly stronger than ipamorelin) makes this combination preferred in protocols targeting caloric surplus and mass accumulation.
Tesamorelin
Tesamorelin stimulates pulsatile growth hormone (GH) release from the pituitary, raising serum IGF-1 and preferentially reducing visceral adipose tissue (VAT). FDA-registration trials (Falutz et al., NEJM 2007; JAIDS 2010) showed ~15% VAT reduction versus placebo over 26 weeks. Later randomized trials (Stanley et al., JAMA 2014; Lancet HIV 2019) extended the evidence to liver fat, showing meaningful reductions in hepatic fat fraction and attenuated fibrosis progression in HIV-associated NAFLD.
This comparison aggregates public research and structured profile data for informational purposes only. It is not medical advice and does not recommend either compound for human use. Consult a qualified healthcare provider before considering any peptide.